Abstract
We recently reported findings that loss of cortical acetylcholinesterase (AChE) activity is greater in parkinsonian dementia than in Alzheimer’s disease (AD). In this study we determined cognitive correlates of in vivo cortical AChE activity in patients with parkinsonian dementia (PDem, n = 11), Parkinson’s disease without dementia (PD, n = 13), and in normal controls (NC, n = 14) using N–[11C]methyl–piperidin–4–yl propionate ([11C]PMP) AChE positron emission tomography (PET). Cortical AChE activity was significantly reduced in the PDem (–20.9%) and PD (–12.7 %) subjects (P < 0.001) when compared with the control subjects. Analysis of the cognitive data within the patient groups demonstrated that scores on the WAIS-III Digit Span, a test of working memory and attention, had most robust correlation with cortical AChE activity (R = 0.61, p < 0.005). There were also significant correlations between cortical AChE activity and other tests of attentional and executive functions, such as the Trail Making and Stroop Color Word tests. There was no significant correlation between cortical AChE activity and duration of motor disease (R = –0.01, ns) or severity of parkinsonian motor symptoms (R = 0.14, ns). We conclude that cortical cholinergic denervation in PD and parkinsonian dementia is associated with decreased performance on tests of attentional and executive functioning.
Similar content being viewed by others
References
Aarsland D, Mosimann UP, McKeith IG (2004) Role of cholinesterase inhibitors in Parkinson’s disease and dementia with Lewy bodies. J Geriatr Psychiatry Neurol 17:164–171
Arendt T, Bigl V, Arendt A, Tennstedt A (1983) Loss of neurons in the nucleus basalis of Meynert in Alzheimer’s disease, paralysis agitans and Korsakoff ’s Disease. Acta Neuropathol (Berl) 61:101–108
Bedard MA, Lemay S, Gagnon JF, Masson H, Paquet F (1998) Induction of a transient dysexecutive syndrome in Parkinson’s disease using a subclinical dose of scopolamine. Behav Neurol 11:187–195
Bedard MA, Pillon B, Dubois B, Duchesne N, Masson H, Agid Y (1999) Acute and long-term administration of anticholinergics in Parkinson’s disease: specific effects on the subcorticofrontal syndrome. Brain Cogn 40:289–313
Benton AL, Hamsher K (1976) Multilingual aphasia examination. AJA Associates, Iowa City
Bohnen NI, Kaufer DI, Ivanco L, Lopresti B, Koeppe RA, Davis J, Mathis CA, Moore RY, DeKosky ST (2003) Cortical cholinergic function is more severely affected in Parkinsonian dementia than in Alzheimer’s Disease: an in vivo PET study. Arch Neurol 60:1745–1748
Bohnen NI, Kaufer DI, Hendrickson R, Ivanco LS, Lopresti B, Koeppe RA, Meltzer CC, Constantine G, Davis JG, Mathis CA, DeKosky ST, Moore RY (2005) Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer’s disease. J Neurol Neurosurg Psychiatry 76:315–319
Boller F, Mizutani T, Roessmann U, Gambetti P (1980) Parkinson’s disease, dementia and Alzheimer’s disease: clinicopathologic correlations. Ann Neurol 7:329–335
Candy JM, Perry RH, Perry EK, Irving D, Blessed G, Fairbairn AF, Tomlinson BE (1983) Pathological changes in the nucleus of Meynert in Alzheimer’s and Parkinson’s diseases. J Neurol Sci 59:277–289
Cooper JA, Sagar HJ, Doherty SM, Jordan N, Tidswell P, Sullivan EV (1992) Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson’s disease. A follow-up study of untreated patients. Brain 115:1701–1725
Delis DC, Kramer JH, Kaplan E, Ober BA (1987) California Verbal Learning Test: Adult Version. The Psychological Corporation, San Antonio, TX
DSM-IV (1994) Diagnostic and Statistical Manual of Mental Disorders. 4th ed., American Psychiatric Association, Washington, DC
Dubois B, Pillon B, Lhermitte F, Agid Y (1990) Cholinergic deficiency and frontal dysfunction in Parkinson’s disease. Ann Neurol 28:117–121
Dubois B, Danze F, Pillon B, Cusimano G, Lhermitte F, Agid Y (1987) Cholinergic- dependent cognitive deficits in Parkinson’s disease. Ann Neurol 22:26–30
Fahn S, Elton R. Members of the UPDRS development committee (1987) Unified Parkinson’s disease rating scale. In: Fahn S, Marsden C, Calne D, Goldstein M (eds) Recent developments in Parkinson’s disease. Macmillan Healthcare Information, Florham Park, NJ, pp 153–164
Folstein MF, Folstein SE, McHugh PR (1975) Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatry Res 12:189–198
Gibb W (1989) Dementia and Parkinson’s disease. Br J Psychiatry 154:596–614
Gotham AM, Brown RG, Marsden CD (1988) ‘Frontal’ cognitive function in patients with Parkinson’s disease ‘on’ and ‘off ’ levodopa. Brain 111:299–321
Irie T, Fukushi K, Akimoto Y, Tamagami H, Nozaki T (1994) Design and evaluation of radioactive acetylcholine analogs for mapping brain acetylcholinesterase (AChE) in vivo. Nucl Med Biol 21:801–808
Koeppe RA, Frey KA, Snyder SE, Meyer P, Kilbourn MR, Kuhl DE (1999) Kinetic modeling of N-[11C]methylpiperidin-4-yl propionate: alternatives for analysis of an irreversible positron emission tomography tracer for measurement of acetylcholinesterase activity in human brain. J Cereb Blood Flow Metab 19:1150–1163
Korczyn AD (2001) Dementia in Parkinson’s disease. J Neurol 248(Suppl 3):III/1–III/4
Kuhl DE, Koeppe RA, Minoshima S, Snyder SE, Ficaro EP, Foster NL, Frey KA, Kilbourn MR (1999) In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer’s disease. Neurology 52:691–699
Lees AJ, Smith E (1983) Cognitive deficits in the early stages of Parkinson’s disease. Brain 106:257–270
Lezak M (1995) Neuropsychological Assessment. Oxford University Press, New York, NY
Mahler ME, Cummings JL (1990) Alzheimer disease and the dementia of Parkinson disease: Comparative investigations. Alz Dis Ass Dis 4:133–149
Mattila PM, Roytta M, Lonnberg P, Marjamaki P, Helenius H, Rinne JO (2001) Choline acetyltransferase activity and striatal dopamine receptors in Parkinson’s disease in relation to cognitive impairment. Acta Neuropathol (Berl) 102:160–166
McKeith IG, Perry EK, Perry RH (1999) Report of the second dementia with Lewy body international workshop. Diagnosis and treatment. Neurology 53:902–905
Nakano I, Hirano A (1984) Parkinson’s disease: neuron loss in the nucleus basalis without concomitant Alzheimer’s disease. Ann Neurol 5:415–418
Namba H, Iyo M, Fukushi K, Shinotoh H, Nagatsuka S, Suhara T, Sudo Y, Suzuki K, Irie T (1999) Human cerebral acetylcholinesterase activity measured with positron emission tomography: procedure, normal values and effect of age. Eur J Nucl Med 26:135–143
Perry EK, Curtis M, Dick DJ, Candy JM, Atack JR, Bloxham CA, Blessed G, Fairbairn A, Tomlinson BE, Perry RH (1985) Cholinergic correlates of cognitive impairment in Parkinson’s disease: comparisons with Alzheimer’s disease. J Neurol Neurosurg Psychiatry 48:413–421
Reitan R (1958) Validity of the Trailmaking Tests as an indication of organic brain damage. Mot Skills 8:271–276
Rogers JD, Brogan D, Mirra SS (1985) The nucleus basalis of Meynert in neurological disease: a quantitative morphological study. Ann Neurol 17:163–170
Ruberg M, Rieger F, Villageois A, Bonnet AM, Agid Y (1986) Acetylcholinesterase and butyrylcholinesterase in frontal cortex and cerebrospinal fluid of demented and non-demented patients with Parkinson’s disease. Brain Res 362:83–91
Snyder SE, Tluczek L, Jewett DM, Nguyen TB, Kuhl DE, Kilbourn MR (1998) Synthesis of 1-[11C]methylpiperidin- 4-yl propionate ([11C]PMP) for in vivo measurements of acetylcholinesterase activity. Nucl Med Biol 25:751–754
Stern Y, Mayeux R, Rosen J, Ilson J (1983) Perceptual motor dysfunction in Parkinson’s disease: a deficit in sequential and predictive voluntary movement. J Neurol Neurosurg Psychiatry 46:145–151
Tagliavini F, Pilleri G, Bouras C, Constantinidis J (1984) The basal nucleus of Meynert in idiopathic Parkinson’s disease. Acta Neurol Scand 70:20–28
Talairach J, Tournoux P (1988) Coplanar stereotaxic atlas of the human brain. Thieme, New York
Tanaka N, Fukushi K, Shinotoh H, Nagatsuka S, Namba H, Iyo M, Aotsuka A, Ota T, Tanada S, Irie T (2001) Positron emission tomographic measurement of brain acetylcholinesterase activity using N-[11C]methylpiperidin-4-yl acetate without arterial blood sampling: methodology of shape analysis and its diagnostic power for Alzheimer’s disease. J Cereb Blood Flow Metab 21:295–306
Wechsler D (1997) Wechsler Adult Intelligence Scale-Third Edition. Psychological Corporation, San Antonio, TX
Weinhard K (1998) Applications of 3D PET. In: Bendriem B, Townsend DW (eds) The theory and practice of 3D PET. Kluwer Academic Publishers, Boston, pp 133–167
Whitehouse PJ, Hedreen JC, White CL, Price DL (1983) Basal forebrain neurons in the dementia of Parkinson disease. Ann Neurol 13:243–248
Wiseman MB, Nichols TE, Woods RP, Sweeney JA, Mintun MA (1996) Stereotaxic techniques comparing foci intensity and location of activation areas in the brain as obtained using positron emission tomography (PET). J Nucl Med 36(Suppl):93P
Woods RP, Mazziota JC, Cherry SR (1993) MRI-PET registration with automated algorithm. J Comput Assist Tomogr 17:536–546
Author information
Authors and Affiliations
Corresponding author
Additional information
Supported by grants from the Department of Veterans Affairs, National Institute of Aging (Alzheimer Disease Research Center, AG05133), and The Scaife Family Foundation, Pittsburgh, PA, USA.
Rights and permissions
About this article
Cite this article
Bohnen, N.I., Kaufer, D.I., Hendrickson, R. et al. Cognitive correlates of cortical cholinergic denervation in Parkinson’s disease and parkinsonian dementia. J Neurol 253, 242–247 (2006). https://doi.org/10.1007/s00415-005-0971-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00415-005-0971-0